FMP

FMP

Enter

CRL - Charles River Labora...

photo-url-https://images.financialmodelingprep.com/symbol/CRL.png

Charles River Laboratories International, Inc.

CRL

NYSE

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

171.04 USD

4.11 (2.4%)

CRL Financial Statements

Year

2024

2023

2022

2021

CF from Operating Activities

734.58M

683.9M

619.64M

760.8M

Net Income

25.29M

480.37M

492.61M

398.84M

Depreciation & Amortization

361.74M

314.12M

303.87M

265.54M

Deferred Income Taxes

-67.43M

-50.9M

-35.88M

-24.01M

Stock Based Compensation

69.89M

72.05M

73.62M

71.47M

Change in Working Capital

-30.33M

-102.38M

-152.55M

42.94M

Accounts Receivable

21.61M

-33.43M

-150.57M

-26.63M

Inventory

16.8M

-62.3M

-78.52M

-25.16M

Accounts Payable

-14.27M

-20.43M

-2.65M

44.9M

Other Working Capital

-54.47M

13.78M

79.19M

49.83M

Other Non-Cash Items

375.41M

-29.36M

-62.02M

6.01M

CF from Investing Activities

-245.09M

-563.15M

-607.92M

-1.44B

Investments in Property, Plant & Equipment

-232.97M

-318.53M

-324.73M

-228.77M

Net Acquisitions

-5.48M

-194.78M

-120.12M

-1.17B

Investment Purchases

-52.88M

-54.22M

-158.27M

-45.55M

Sales/Maturities of Investments

41.69M

6.67M

4.55M

6.53M

Other Investing Activites

4.55M

-2.29M

-9.35M

264k

CF from Financing Activities

-550.93M

-85.52M

-42.4M

672.6M

Debt Repayment

-412.19M

-75.32M

-2.93B

-6.24B

Common Stock Issued

0

0

0

0

Common Stock Repurchased

-119.17M

-24.16M

-38.65M

-40.71M

Dividends Paid

0

0

0

0

Other Financing Activites

-19.56M

13.96M

-23.54M

43.32M

Free Cash Flow

501.61M

365.37M

294.91M

532.03M

Operating Cash Flow

734.58M

683.9M

619.64M

760.8M

Capital Expenditures

-232.97M

-318.53M

-324.73M

-228.77M

Cash at Beginning of Period

284.48M

241.21M

246.31M

233.12M

Cash at End of Period

205.57M

284.48M

241.21M

246.31M

Net Change In Cash

-78.91M

43.27M

-5.1M

13.2M

Retained Earning Schedule

Year

2024

2023

2022

2021

Retained Earnings (Previous Year)

1.89B

1.43B

980.75M

625.41M

Net Income

22.2M

474.62M

486.23M

390.98M

Stock Repurchases

-119.17M

-24.16M

-38.65M

-40.71M

Dividend Paid

0

0

0

0

Retained Earnings

1.81B

1.89B

1.43B

980.75M

Other Distributions

-194.29M

430.16M

413.5M

314.63M

PPE Schedule

Year

2024

2023

2022

2021

Gross PPE

2.02B

2.03B

1.86B

1.58B

Annual Depreciation

361.74M

314.12M

303.87M

265.54M

Capital Expenditure

-232.97M

-318.53M

-324.73M

-228.77M

Net PPE

1.89B

2.04B

1.88B

1.55B

Intangible and Goodwill Schedule

Year

2024

2023

2022

2021

Acquisitions and Adjustments

-248.44M

245.14M

138.02M

902.71M

Goodwill (Previous Year)

3.1B

2.85B

2.71B

1.81B

Goodwill

2.85B

3.1B

2.85B

2.71B

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep